Capmatinib Recruiting Phase 2 Trials for Malignancies / MET Gene Mutation / Lung Cancer Metastatic Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03693339Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation